Cataracts and CrystallinsWe often think of cataracts as a problem that people living in 'developing countries' face and so it may surprise you to learn that every year, around 120,000 people in the UK have surgery to remove cataracts. Although cataracts result from many conditions, the most frequent cause is the natural aging process. Other causes can include injury, chronic eye disease and diseases such as diabetes. More than half the people over age 65 have some degree of cataract development and cataracts can take from a few months to several years to develop.
A cataract is a clouding of a part of the eye known as the lens The eye lens
The eye lens not only contains some of the oldest cells in an organism, but also the oldest proteins since, in the centre of the lens nucleus, there is no protein turnover during the lifetime of an individual. Thus, there is a requirement for both stability and longevity of lens proteins, the majority of which belong to a single family of proteins called the crystallins. (These proteins are called "crystallins" because the ancient Greeks considered the lens to be "ice-like" in appearance). This extreme biological situation has led to the selection of very stable proteins and also to an enrichment of protein chaperones in the lens. The term "chaperone" has been borrowed from Victorian escorts and, as the term implies, refers to the ability of these proteins to associate with other proteins. Stress conditions such as heat, oxidation and exposure to heavy metals result in destabilisation of proteins, which can lead to aggregation and precipitation; chaperones recognise and bind to these non-native protein conformations and prevent aberrant protein-protein interactions.
The major protein chaperones that are expressed at high levels in the lens are the a-crystallins and these may serve a protective role in the lens by binding to unfolded proteins, preventing precipitation through the formation of a stable complex. As a result, any potential contribution of a precipitate to cataract formation may be minimised. The lens therefore appears well equipped to deal with any aberrant forms of proteins that might develop and perturb its properties. Nonetheless, lens function can be abrogated by the formation of either inherited or sporadic lens cataracts (see figure 3).
The g-crystallins were characterised as major lens proteins over
a century ago and several mutations in the g-crystallin genes that
lead to cataract have been identified in mice and humans. In preliminary
work Cait's group (in a major research effort involving groups both
in the UK and overseas) have demonstrated that cataract formation
in mice that have a mutant form of g-crystallin is due to the formation
in the eye lens of structures known as amyloid fibrils. Amyloid
fibrils are very stable protein aggregates well-known to medicine:
they are involved in a wide range of diseases including Alzheimer's
disease and type-II diabetes. In the case of the mutant mice, the
normally liquid-like "sack" of the lens fibre cell becomes
enriched in fibrous aggregates (see Figure 4). Although the role
of amyloid fibrils in diseases like Alzheimer's disease is unclear,
in the case of cataract the most likely role of the aggregates is
simply to scatter light, causing lens fogging.
Future research goals Cataracts do not, however, just occur in people (or mice) with a mutation in one of their crystallin proteins. Indeed, the vast majority of cataracts are age-related, and do not appear to have anything to do with inherited mutations. Cait's group is now working to discover whether "normal" eye lens proteins - the proteins in the lenses of most of us - also form these amyloid fibrils. This is a viable hypothesis since many of the environmental factors linked to cataract - diabetes, UV exposure, contact with chemicals - are known to also change the structure of proteins and may therefore drive the formation of fibrous aggregates. If this is indeed the case, then age-related cataract can be placed in the amyloid family of diseases, and many of the therapeutic strategies under investigation to prevent amyloid fibril formation in diseases like Alzheimer's disease may also be of use to cataract sufferers. ABOUT THE AUTHORS: Dr. Cait MacPhee is a biophysicist and a Royal Society University Research Fellow at the University of Cambridge Cavendish Laboratory. Dr. Karen Smith is a neuroanatomist and the Business Development Manager for Life Sciences at the University of Cambridge Corporate Liaison Office (CLO). ACKNOWLEDGEMENTS: * Courtesy of St Lukes Cataract and Lazer Institute
- September 2004 About the AuthorDr Karen Smith is a neuroanatomist. She was the Business Director of the Cambridge Computational Biology Institute and is now the Director of Bioprocess Leadership, Biochemical Engineering, University College London. |
||||||||||||||||||||||
The contents of this site are © The Naked Scientists® 2000-2008. The Naked Scientists® and Naked Science® are registered trademarks. |
||||||||||||||||||||||